IFN-α promotes the rapid differentiation of monocytes from patients with chronic myeloid leukemia into activated dendritic cells tuned to undergo full maturation after LPS treatment

被引:65
作者
Gabriele, L
Borghi, P
Rozera, C
Sestili, P
Andreotti, M
Guarini, A
Montefusco, E
Foà, R
Belardelli, F
机构
[1] Ist Super Sanita, Virol Lab, I-00161 Rome, Italy
[2] Univ Roma La Sapienza, Dept Cellular Biotechnol & Hematol, Rome, Italy
关键词
D O I
10.1182/blood-2003-03-0981
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Chronic myelogenous leukemia (CML) is a malignant myeloproliferative disease arising from the clonal expansion of a stem cell expressing the bcr/abl oncogene. CML patients frequently respond to treatment with interferon-alpha (IFNI-alpha), even though the mechanisms of the response remain unclear. In the present study, we evaluated the role of IFNI-a in differentiation and activity of monocyte-derived dendritic cells (DCs) from CML patients as well as in modulation of the cell response to popolysaccharide (LPS). Treatment of CML monocytes with IFN-alpha and granulocyte-macrophage colony-stimulating factor (GM-CSF) resulted in the rapid generation of activated DCs (CML-IFN-DCs) expressing interleukin-15 (IL-15) and the antiapoptotic bcl-2 gene. These cells were fully competent to induce IFN-gamma production by cocultured autologous T lymphocytes and expansion of CD8(+) T cells. LPS treatment of CML-IFN-DCs, but not of immature DCs generated in the presence of IL-4/GM-CSF, induced the generation of CD8+ T cells reactive against autologous leukemic CD34(+) cells. Altogether, these results suggest that (1) the generation of highly active monocyte-derived DCs could be important for the induction of an antitumor response in IFN-treated CML patients and (2) IFN-alpha can represent a valuable cytokine for the rapid generation of active monocyte-derived DCs to be utilized for vaccination strategies of CML patients.
引用
收藏
页码:980 / 987
页数:8
相关论文
共 54 条
[1]   Immunobiology of dendritic cells [J].
Banchereau, J ;
Briere, F ;
Caux, C ;
Davoust, J ;
Lebecque, S ;
Liu, YT ;
Pulendran, B ;
Palucka, K .
ANNUAL REVIEW OF IMMUNOLOGY, 2000, 18 :767-+
[2]   The neglected role of type I interferon in the T-cell response: Implications for its clinical use [J].
Belardelli, F ;
Gresser, I .
IMMUNOLOGY TODAY, 1996, 17 (08) :369-372
[3]   Cytokines as a link between innate and adaptive antitumor immunity [J].
Belardelli, F ;
Ferrantini, M .
TRENDS IN IMMUNOLOGY, 2002, 23 (04) :201-208
[4]   Interferon-alpha in tumor immunity and immunotherapy [J].
Belardelli, F ;
Ferrantini, M ;
Proietti, E ;
Kirkwood, JM .
CYTOKINE & GROWTH FACTOR REVIEWS, 2002, 13 (02) :119-134
[5]   ROLE OF INTERFERONS AND OTHER CYTOKINES IN THE REGULATION OF THE IMMUNE-RESPONSE [J].
BELARDELLI, F .
APMIS, 1995, 103 (03) :161-179
[6]   Imatinib and chronic-phase leukemias [J].
Boros, LG ;
Lee, WP ;
Cascante, M .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (01) :67-68
[7]   Dendritic cells in cancer vaccines [J].
Brossart, P ;
Wirths, S ;
Brugger, W ;
Kanz, L .
EXPERIMENTAL HEMATOLOGY, 2001, 29 (11) :1247-1255
[8]   Imatinib: the first 3 years [J].
Capdeville, R ;
Silberman, S ;
Dimitrijevic, S .
EUROPEAN JOURNAL OF CANCER, 2002, 38 :S77-S82
[9]   Interferon alpha in combination with GM-CSF induces the differentiation of leukaemic antigen-presenting cells that have the capacity to stimulate a specific anti-leukaemic cytotoxic T-cell response from patients with chronic myeloid leukaemia [J].
Chen, X ;
Regn, S ;
Raffegerst, S ;
Kolb, HJ ;
Roskrow, M .
BRITISH JOURNAL OF HAEMATOLOGY, 2000, 111 (02) :596-607
[10]  
Claxton DF, 2001, CRIT REV IMMUNOL, V21, P147